Keynote: Integrated Risk/Benefit Assessment to Inform Decision Making in Drug Discovery

Monday, October 17, 2022

1:30 PM – 2:30 PM ET

Location:253 C

Keynote Speaker(s)

Thierry Lavé, PhD (he/him/his)

Head R&D Academy and Faculty
Hoffman-la Roche Inc
Basel, Basel-Stadt, Switzerland

Moderator(s)

Christine Bowman, PhD

Senior Scientist
Genentech

Integrated Risk/Benefit Assessment to Inform Decision Making in Drug Discovery requires a true culture of collaboration of various scientific disciplines and across functions to enable acceleration of compounds from discovery to the clinic and to maximize the therapeutic benefit of our medicines. This will be exemplified in the presentation with relevant use cases.

Learning Objectives:

Understand the opportunities we create for patients, society and R&D organisations
Understand the importance of integrated aproaches to assess risk benefit for the patient in order to support good decision making
Understand how we can leverage innovations coming from computation, advnaced in vitro systems and improved access to patient data and how it will transform R&D